For the quarter ending 2025-09-30, HRTX had $26,552K increase in cash & cash equivalents over the period. $1,331K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -17,241 | - |
| Loss on disposal of property and equipment | - | -95 |
| Stock-based compensation expense | 2,852 | 5,308 |
| Depreciation and amortization | 615 | 1,162 |
| Amortization of debt discount | 194 | 311 |
| Amortization of debt issuance costs | 2 | 106 |
| Accretion of discount on short-term investments | 130 | 520 |
| Retirement and impairment of property and equipment | 409 | - |
| Loss on extinguishment of debt | -11,339 | - |
| Accounts receivable | 1,116 | 1,050 |
| Net loss | - | 254 |
| Inventory | -2,940 | 19,805 |
| Prepaid expenses and other assets | 5,248 | -698 |
| Accounts payable | -20 | 328 |
| Accrued clinical and manufacturing liabilities | 2,296 | -8,083 |
| Accrued payroll and employee related liabilities | 2,277 | -3,083 |
| Other accrued expenses | 2,511 | 4,541 |
| Net cash used in operating activities | 1,331 | -19,738 |
| Purchases of short-term investments | 6,127 | 32,087 |
| Maturities and sales of short-term investments | 17,956 | 41,958 |
| Purchases of property and equipment | 0 | 317 |
| Proceeds from sale of property and equipment | 29 | 53 |
| Net cash provided by investing activities | 11,858 | 9,607 |
| Proceeds from the sale of common stock | 19,838 | - |
| Cash paid for issuance costs of stock | 1,531 | - |
| Proceeds from sale of series a convertible preferred stock | 7,862 | - |
| Cash paid for extinguishment-Two Thousand Twenty Six Senior Unsecured Convertible Notes | 125,000 | - |
| Cash paid for extinguishment-Notes Payable | 25,000 | - |
| Proceeds from notes payable issuance-Two Thousand Thirty One Senior Unsecured Convertible Notes | 33,250 | - |
| Cash paid for notes payable debt issuance cost-Two Thousand Thirty One Senior Unsecured Convertible Notes | 1,386 | - |
| Proceeds from notes payable issuance-Notes Payable | 108,787 | - |
| Cash paid for notes payable debt issuance cost-Notes Payable | 3,406 | - |
| Proceeds from purchases under the employee stock purchase plan | 0 | 587 |
| Receipts for stock issued under the equity incentive plan | -51 | 258 |
| Net cash provided by financing activities | 13,363 | 845 |
| Net increase (decrease) in cash and cash equivalents | 26,552 | -9,286 |
| Cash and cash equivalents at beginning of period | 25,802 | - |
| Cash and cash equivalents at end of period | 43,068 | - |
HERON THERAPEUTICS, INC. DE (HRTX)
HERON THERAPEUTICS, INC. DE (HRTX)